Literature DB >> 24211536

Centrosomal abnormalities characterize human and rodent cystic cholangiocytes and are associated with Cdc25A overexpression.

Tatyana V Masyuk1, Seung-Ok Lee2, Brynn N Radtke1, Angela J Stroope1, Bing Huang1, Jesús M Banales3, Anatoliy I Masyuk1, Patrick L Splinter1, Sergio A Gradilone1, Gabriella B Gajdos1, Nicholas F LaRusso4.   

Abstract

Hepatic cystogenesis in polycystic liver diseases is associated with abnormalities of cholangiocyte cilia. Given the crucial association between cilia and centrosomes, we tested the hypothesis that centrosomal defects occur in cystic cholangiocytes of rodents (Pkd2(WS25/-) mice and PCK rats) and of patients with polycystic liver diseases, contributing to disturbed ciliogenesis and cyst formation. We examined centrosomal cytoarchitecture in control and cystic cholangiocytes, the effects of centrosomal abnormalities on ciliogenesis, and the role of the cell-cycle regulator Cdc25A in centrosomal defects by depleting cholangiocytes of Cdc25A in vitro and in vivo and evaluating centrosome morphology, cell-cycle progression, proliferation, ciliogenesis, and cystogenesis. The cystic cholangiocytes had atypical centrosome positioning, supernumerary centrosomes, multipolar spindles, and extra cilia. Structurally aberrant cilia were present in cystic cholangiocytes during ciliogenesis. Depletion of Cdc25A resulted in i) a decreased number of centrosomes and multiciliated cholangiocytes, ii) an increased fraction of ciliated cholangiocytes with longer cilia, iii) a decreased proportion of cholangiocytes in G1/G0 and S phases of the cell cycle, iv) decreased cell proliferation, and v) reduced cyst growth in vitro and in vivo. Our data support the hypothesis that centrosomal abnormalities in cholangiocytes are associated with aberrant ciliogenesis and that accelerated cystogenesis is likely due to overexpression of Cdc25A, providing additional evidence that pharmacological targeting of Cdc25A has therapeutic potential in polycystic liver diseases.
Copyright © 2014 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24211536      PMCID: PMC3873494          DOI: 10.1016/j.ajpath.2013.09.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  38 in total

1.  Flies without centrioles.

Authors:  Renata Basto; Joyce Lau; Tatiana Vinogradova; Alejandra Gardiol; C Geoffrey Woods; Alexey Khodjakov; Jordan W Raff
Journal:  Cell       Date:  2006-06-30       Impact factor: 41.582

Review 2.  Centriole/basal body morphogenesis and migration during ciliogenesis in animal cells.

Authors:  Helen R Dawe; Helen Farr; Keith Gull
Journal:  J Cell Sci       Date:  2007-01-01       Impact factor: 5.285

3.  Centrioles: duplicating precariously.

Authors:  Laurence Pelletier
Journal:  Curr Biol       Date:  2007-09-04       Impact factor: 10.834

Review 4.  Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease?

Authors:  Friedhelm Hildebrandt; Edgar Otto
Journal:  Nat Rev Genet       Date:  2005-12       Impact factor: 53.242

Review 5.  Centrosome amplification, chromosome instability and cancer development.

Authors:  Kenji Fukasawa
Journal:  Cancer Lett       Date:  2005-12-08       Impact factor: 8.679

Review 6.  Renal cystic disease: the role of the primary cilium/centrosome complex in pathogenesis.

Authors:  Brian J Siroky; Lisa M Guay-Woodford
Journal:  Adv Chronic Kidney Dis       Date:  2006-04       Impact factor: 3.620

7.  Defects in cholangiocyte fibrocystin expression and ciliary structure in the PCK rat.

Authors:  Tatyana V Masyuk; Bing Q Huang; Christopher J Ward; Anatoliy I Masyuk; David Yuan; Patrick L Splinter; Rachaneekorn Punyashthiti; Eric L Ritman; Vicente E Torres; Peter C Harris; Nicholas F LaRusso
Journal:  Gastroenterology       Date:  2003-11       Impact factor: 22.682

8.  A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation.

Authors:  J R Woollard; R Punyashtiti; S Richardson; T V Masyuk; S Whelan; B Q Huang; D J Lager; J vanDeursen; V E Torres; V H Gattone; N F LaRusso; P C Harris; C J Ward
Journal:  Kidney Int       Date:  2007-05-23       Impact factor: 10.612

9.  Centrosomes: keeping tumors in check.

Authors:  Laurence Pelletier
Journal:  Curr Biol       Date:  2008-08-26       Impact factor: 10.834

10.  Centrosome positioning in interphase cells.

Authors:  Anton Burakov; Elena Nadezhdina; Boris Slepchenko; Vladimir Rodionov
Journal:  J Cell Biol       Date:  2003-09-15       Impact factor: 10.539

View more
  12 in total

1.  Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.

Authors:  Patricia Munoz-Garrido; José J G Marin; María J Perugorria; Aura D Urribarri; Oihane Erice; Elena Sáez; Miriam Úriz; Sarai Sarvide; Ainhoa Portu; Axel R Concepcion; Marta R Romero; María J Monte; Álvaro Santos-Laso; Elizabeth Hijona; Raúl Jimenez-Agüero; Marco Marzioni; Ulrich Beuers; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Joost P H Drenth; Jesús M Banales
Journal:  J Hepatol       Date:  2015-06-01       Impact factor: 25.083

2.  TGR5 in the Cholangiociliopathies.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Dig Dis       Date:  2015-05-27       Impact factor: 2.404

Review 3.  Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases.

Authors:  Luca Fabris; Romina Fiorotto; Carlo Spirli; Massimiliano Cadamuro; Valeria Mariotti; Maria J Perugorria; Jesus M Banales; Mario Strazzabosco
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2019-08       Impact factor: 46.802

Review 4.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

5.  Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.

Authors:  Maria Lorenzo Pisarello; Tatyana V Masyuk; Sergio A Gradilone; Anatoliy I Masyuk; Jingyi F Ding; Pui-Yuen Lee; Nicholas F LaRusso
Journal:  Am J Pathol       Date:  2018-01-31       Impact factor: 4.307

Review 6.  Genetics, pathobiology and therapeutic opportunities of polycystic liver disease.

Authors:  Paula Olaizola; Pedro M Rodrigues; Francisco J Caballero-Camino; Laura Izquierdo-Sanchez; Patricia Aspichueta; Luis Bujanda; Nicholas F Larusso; Joost P H Drenth; Maria J Perugorria; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2022-05-13       Impact factor: 73.082

Review 7.  Therapeutic Targets in Polycystic Liver Disease.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Curr Drug Targets       Date:  2017       Impact factor: 3.465

8.  Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.

Authors:  Anatoliy I Masyuk; Tatyana V Masyuk; Maria J Lorenzo Pisarello; Jingyi Francess Ding; Lorena Loarca; Bing Q Huang; Nicholas F LaRusso
Journal:  Hepatology       Date:  2018-02-01       Impact factor: 17.425

Review 9.  Polycystic Liver Disease: Advances in Understanding and Treatment.

Authors:  Tatyana V Masyuk; Anatoliy I Masyuk; Nicholas F LaRusso
Journal:  Annu Rev Pathol       Date:  2021-11-01       Impact factor: 23.472

10.  Autophagy promotes hepatic cystogenesis in polycystic liver disease by depletion of cholangiocyte ciliogenic proteins.

Authors:  Anatoliy I Masyuk; Tatyana V Masyuk; Christy E Trussoni; Nicholas E Pirius; Nicholas F LaRusso
Journal:  Hepatology       Date:  2022-02-08       Impact factor: 17.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.